Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesVyne Therapeutics Inc

Vyne Therapeutics Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
None USD 0.00(0%)
Last update at 2026-11-10T18:24:20.301519Z
Market Cap
37.63M

Momentum Score

…

VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
1.67
Low
6.79
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Vyne Therapeutics Inc is a NASDAQ-listed biopharmaceutical company developing therapeutic candidates intended to address unmet medical needs. Long-term growth may be driven by progress across its development programs, regulatory approvals, potential licensing or partnerships and eventual commercialization, which could support pipeline value and future revenue generation.

Principal risks include clinical and regulatory failure, limited or no commercial revenue, the need for additional financing and resulting dilution, competitive pressures and execution challenges in bringing therapies to market.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
-
Dividend Yield
-
Revenue TTM
0.42M
Revenue Per Share
0.02
Gross Profit TTM
0.48M
Debt / Equity
0.00
ROE
-51.91%
Net Debt
-30.46M
ROCE
-38.04%
Diluted EPS TTM
-1.13

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -33.93M -73.78M -255.83M -73.70M -51.45M
Net income -33.95M -73.33M -255.57M -70.46M -51.45M
Selling general administrative 16.39M 54.48M 89.54M 22.48M 12.19M
Gross profit 0.48M 11.41M 19.60M - 10.64M
Reconciled depreciation 0.07M 0.11M 0.34M 0.70M 0.02M
Ebit -34.30M -68.03M -113.47M -76.94M -54.56M
Ebitda -33.93M -68.17M -112.02M -76.24M -54.53M
Depreciation and amortization 0.36M -0.14M 1.45M 0.70M 0.02M
Operating income -34.30M -68.03M -113.47M -76.24M -54.53M
Other operating expenses 34.77M 82.79M 134.47M 76.24M 65.17M
Interest expense 10.81M 5.61M 4.39M 2.54M 3.09M
Tax provision 0.01M -0.45M -0.26M - -
Interest income - - - - 3.09M
Net interest income 0.00M -5.61M -4.39M 2.54M 3.09M
Income tax expense 0.01M -0.45M -0.26M -3.24M 3.09M
Total revenue 0.48M 14.76M 20.99M 0.00M 10.64M
Total operating expenses 34.77M 79.44M 133.08M 76.24M 65.17M
Cost of revenue - 3.35M 1.39M - -
Total other income expense net 0.36M -5.75M -142.35M 2.54M 3.09M
Discontinued operations 10.73M -29.12M -29.12M -29.12M -
Net income from continuing ops -33.95M -73.33M -255.57M -73.70M -51.45M
Net income applicable to common shares -23.21M -73.33M -255.57M -95.18M -74.16M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 97.69M 40.76M 67.05M 93.74M 79.17M
Other current assets 2.66M 7.19M 0.34M 5.45M 1.38M
Total liab 8.95M 9.56M 18.41M 56.25M 10.66M
Total stockholder equity 88.73M 31.20M 48.64M 37.49M 68.51M
Other current liab 5.76M 6.96M 11.55M 0.10M 0.48M
Common stock 0.00M 1.47M 0.01M 0.00M 0.00M
Capital stock 0.00M 0.00M 0.01M 0.00M 0.00M
Retained earnings -691.34M -662.74M -639.52M -566.20M -184.34M
Other liab - - - 0.77M 0.88M
Good will - - - 4.54M -
Other assets - 2.48M 3.51M 4.90M 0.74M
Cash 30.67M 30.91M 42.25M 57.56M 30.78M
Total current liabilities 7.54M 9.35M 18.41M 21.45M 10.66M
Current deferred revenue - - - 15.81M 5.71M
Net debt -30.46M -31.26M -41.90M -22.78M -30.08M
Short term debt 0.12M - 0.35M 0.76M 0.70M
Short long term debt total 0.21M -0.35M 0.35M 34.78M 0.70M
Other stockholder equity 780.04M 692.26M 688.16M 603.68M 252.82M
Property plant equipment - - 0.35M 2.14M 4.58M
Total current assets 95.96M 38.27M 63.19M 87.26M 78.33M
Net tangible assets - 31.20M 48.64M 37.49M 17.57M
Short term investments 62.63M - 0.00M 1.03M 46.17M
Net receivables - 5.17M 7.58M 15.82M 0.14M
Long term debt - - - 33.17M -
Inventory - 0.10M 7.29M 7.40M 1.36M
Accounts payable 1.66M 2.39M 6.51M 4.78M 3.77M
Accumulated other comprehensive income 0.03M - - - 0.02M
Common stock total equity - - - 0.00M 0.00M
Non currrent assets other 1.51M 2.20M 3.51M 4.34M 0.07M
Non current assets total 1.72M 2.48M 3.86M 6.48M 0.84M
Capital lease obligations 0.21M 0.00M 0.35M 1.61M 0.70M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 15.67M 1.03M 89.11M 41.37M -33.88M
Change to liabilities -8.68M -2.67M -12.97M 18.05M 0.24M
Total cashflows from investing activities 15.67M 1.03M 89.11M 41.87M -11.76M
Net borrowings - -36.43M -36.43M 33.90M 33.90M
Total cash from financing activities 1.65M 39.78M 61.81M 4.99M 125.91M
Change to operating activities -0.35M -0.37M -4.17M -0.39M -0.29M
Net income -23.21M -73.33M -255.57M -73.70M -51.45M
Change in cash -11.88M -15.56M 13.83M -18.73M 39.30M
Begin period cash flow 42.85M 58.42M 44.58M 49.51M 10.21M
End period cash flow 30.98M 42.85M 58.42M 30.78M 49.51M
Total cash from operating activities -29.20M -56.37M -137.08M -65.10M -52.73M
Issuance of capital stock 1.68M 75.98M 61.64M 4.53M 125.42M
Depreciation 0.07M 0.11M 0.34M 0.70M 0.02M
Other cashflows from investing activities 15.67M 15.67M 15.67M 15.67M -
Change to inventory 0.10M 0.11M -6.05M -1.36M 2.76M
Change to account receivables 11.21M 7.71M -17.14M 0.37M 0.79M
Other cashflows from financing activities 0.18M 0.23M 0.17M 0.47M 0.50M
Change to netincome -8.34M 12.08M 158.48M 4.75M 5.54M
Capital expenditures 0.00M 0.00M 0.11M 0.01M 0.14M
Change in working capital 2.28M 4.78M -40.33M 1.89M -4.17M
Stock based compensation 4.30M 8.08M 18.10M 6.70M 3.64M
Other non cash items -12.64M 2.47M 84.07M -0.69M -0.77M
Free cash flow -29.20M -56.37M -137.19M -65.11M -52.87M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
NVO
Novo Nordisk A/S		 -0.79
1.90%		 40.59 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -1.97
0.36%		 548.90 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 -9.49
1.03%		 910.47 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Vyne Therapeutics Inc

VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.

685 Route 202/206 N, Bridgewater, NJ, United States, 08807

800 775 7936

https://www.vynetherapeutics.com

10

Name Title Year Born
Mr. David T. Domzalski CEO, Pres & Director 1967
Dr. Iain A. Stuart Ph.D. Chief Scientific Officer 1973
Ms. Mutya Harsch J.D. Gen. Counsel, Chief Legal Officer & Company Sec. 1975
Mr. Tyler Zeronda CFO, Principal Accounting Officer & Treasurer 1986
Mr. David Schuz Sr. VP of Intellectual Property 1954
Dr. Russell Elliott D.Phil. Sr. VP of Pharmaceutical Devel. 1966
Dr. Darrell S. Rigel M.S., M.D., MS Consultant 1950
Mr. David T. Domzalski CEO, President & Director 1967
Ms. Mutya Harsch J.D. General Counsel, Chief Legal Officer & Company Secretary 1975
Mr. Tyler Zeronda CFO & Treasurer 1987

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

PET
CAD 23.20
+7.81%
CHR
CAD 35.00
+6.29%
QTWO
CAD 1.71
+6.21%
IFOS
CAD 1.75
+3.55%
GWO
CAD 94.83
+3.15%
MUX
CAD 18.65
-18.34%
URE
CAD 0.95
-15.93%
WELL
CAD 3.72
-12.47%
ISO
CAD 11.42
-10.22%
SGML
CAD 7.50
-10.18%

Equity Sectors*

  • Basic Materials

    -3.95%

  • Communication Services

    +0.41%

  • Consumer Cyclical

    -0.31%

  • Consumer Defensive

    +0.17%

  • Energy

    -0.32%

  • Financial Services

    +0.02%

  • Healthcare

    -1.76%

  • Industrials

    -0.92%

  • Real Estate

    -0.69%

  • Technology

    -1.20%

  • Utilities

    +0.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…